rais price
updat sales/ep estim
base compani pre-announc exhibit
chang sale estimate incl favor fx higher medsurg
orthoped forecast gm/om/tax estim
remain rel unchang rais pt
ep maintain buy
estim glanc forecast sales/ep
cc organ vs consensu
 syk ep guidanc us/ou
knee forecast cc day adj sale growth
us number exclud assum storm recoveri uplift weve
classifi differ sell day compar
basi year estim around mako tka
unit us may equat around share gain one assum
place competit account price premium inclus
accessori assum us market us ou hip forecast
cc day weather adjust growth compar
basi ww hip estim
cc cc/sd/weather adj report compar consensu
report ww knee estim
cc cc/sd/weather adj report vs consensu
item watch result syk abil drive continu
uptak mako robot knee share overal health global
neg tax reform impact progress sage recoveri lost market
share momentum camera physio control like
impact recent ischem stroke guidelin chang anticip novadaq
rais sale ep estim exhibit rais
sales/ep estim organ cc
report cc organ report
includ vexim revenu exclud entellu
expect close consensu sale estim
growth chang sale estim includ favor fx
higher orthoped medsurg forecast
margin assumpt gm/om/tax remain rel
unchang vs prior continu pg
tr target
rais pt valuat risk like syk reliabl strong sale growth
diversif well upsid potenti via futur accret mako share gain use
rel valuat framework regress forward sale compound-annual-growth-rate vs rel forward peer p/
 assum addit point inorgan growth syk sale compound-annual-growth-rate
get us rel forward price-to-earnings premium convolv day
forward multipl anticip cash earn arriv revis
price target risk includ inabl mako drive share gain hospit capital-expenditure declin
failur deliv margin expans experi eros due acquisit activ
page
exhibit revenu varianc segment product categori
page
strh estimatesactualconsensusno ofstrh vs consensu cc pt handl emerg spineneurotechnolog neurotechnolog total stryker corpor
page
exhibit revenu varianc segment product categori
page
strh estimatesstrhconsensusno strh vs consensu cc pt handl emerg spineneurotechnolog neurotechnolog total stryker corpor
page
page
therapytot incom inc med-tech w/ analysisgross analysissal cc extrem orthoped total neurotech spine ep stryker corpor
global compani provid medic technolog product servic busi
segment orthoped medsurg neurotechnolog spine compani found
homer stryker incorpor headquart kalamazoo mi
believ strength brand us compani proven abil maxim
impact acquir technolog busi upon incorpor syk excel commerci
organ support target price
valuat risk
like syk reliabl strong sale growth diversif well upsid potenti via futur
accret mako share gain use rel valuat framework regress
forward sale compound-annual-growth-rate vs rel forward peer price-to-earnings assum addit point inorgan growth
syk sale compound-annual-growth-rate get us rel forward price-to-earnings premium
convolv day forward multipl anticip cash
earn arriv price target risk includ inabl mako drive
share gain hospit capital-expenditure declin failur deliv margin expans experi eros
due acquisit activ
compani mention note
bruce nudel herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express specif
recommend report
